Q4 May Signal If Winlevi Can Give Wings To Sun’s US Specialty Sales
Executive Summary
Sun-Cassiopea’s first-in-class topical androgen receptor inhibitor, Winlevi, appears off to an encouraging start in the US, generating prescriptions from 80% of targeted physicians. Can it hold out in the competitive acne therapy segment and add sheen to Sun’s specialty portfolio?
You may also be interested in...
Sun Specialty Basket Rx Trends Up, Not Giving Up On Higher Dose Deuruxolitinib
Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.